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Abstract Accumulating evidence suggests that polymor-
phisms in Toll-like receptors (TLRs) influence the patho-
genesis of mycobacterial infections, including leprosy, a
disease whose manifestations depend on host immune
responses. Polymorphisms in TLR2 are associated with an
increased risk of reversal reaction, but not susceptibility to
leprosy itself. We examined whether polymorphisms in
TLR4 are associated with susceptibility to leprosy in a
cohort of 441 Ethiopian leprosy patients and 197 healthy
controls. We found that two single nucleotide polymor-
phisms (SNPs) in TLR4 (896G>A [D299G] and 1196C>T
[T399I]) were associated with a protective effect against the
disease. The 896GG, GA and AA genotypes were found in
91.7, 7.8 and 0.5% of leprosy cases versus 79.9, 19.1 and
1.0% of controls, respectively (odds ratio [OR]=0.34, 95%
confidence interval [CI] 0.20–0.57, P<0.001, additive
model). Similarly, the 1196CC, CT and TT genotypes were
found in 98.1, 1.9 and 0% of leprosy cases versus 91.8, 7.7
and 0.5% of controls, respectively (OR=0.16, 95% CI
0.06-–.40, P<0.001, dominant model). We found that
Mycobacterium leprae stimulation of monocytes partially
inhibited their subsequent response to lipopolysaccharide
(LPS) stimulation. Our data suggest that TLR4 polymor-
phisms are associated with susceptibility to leprosy and that
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this effect may be mediated at the cellular level by the
modulation of TLR4 signalling by M. leprae.
Introduction
Leprosy remains an important public health concern in
developing countries, with an estimated 250,000 new patients
each year [1]. Infection with Mycobacterium leprae is
characterised by a polarised spectrum of clinical manifesta-
tions that correlate with the level and type of cell-mediated
immunity [2, 3]. At one end of the spectrum, tuberculoid
leprosy patients have localised lesions that contain few bacilli
and a Th1 T-cell-mediated cellular immune response [3–5]. At
the opposite end, lepromatous leprosy patients have dissemi-
nated infection with extensive lesions containing numerous
intra-cellular bacilli and a Th2 T-cell-mediated cellular immune
response. This wide range of clinical and immunological
presentations makes leprosy a prototypical disease to under-
stand how polymorphisms in innate immunity genes influence
adaptive immune responses. Furthermore, insights into leprosy
pathogenesis may help elucidate mechanisms of protective
immunity to other mycobacteria such as M. tuberculosis, a
leading cause of morbidity and mortality worldwide.
Toll-like receptors (TLRs) constitute a family of trans-
membrane proteins that play an important role in initiating
the host immune response to various pathogens, including
the pathogenesis of mycobacterial infections [6–8]. The
interaction of specific mycobacterial agonists with TLRs
leads to the production of inflammatory mediators that are
critical for the activation of innate and adaptive immune
responses [9, 10]. Among the members of the TLR family,
TLR2 (as a heterodimer with TLR1 or TLR6), TLR4 and
TLR9 have been shown to interact with mycobacterial
agonists [9–11]. A number of studies have established a
role for the TLR2-mediated recognition of M. tuberculosis,
M. leprae and other non-tuberculous mycobacteria [10, 12].
In vitro data also supported a role for the TLR4-mediated
recognition of an M. tuberculosis ligand that was stimula-
tory only when isolated from live organisms [13].
For decades, host genetic factors have been known to play
an important role in leprosy. Genome-wide studies have
identified several loci that are associated with the disease or
its clinical presentation (reviewed in [14, 15]). In addition,
studies have reported associations between leprosy and/or
leprosy type and polymorphisms in numerous candidate genes,
including the tumour necrosis factor α (TNF-α) gene, the
interleukin-10 gene, the transporter associated with antigen
processing 1 and 2 (TAP1 and TAP2) genes, the natural
resistance associated macrophage protein 1 (NRAMP1) gene
and the vitamin D receptor gene (reviewed in [14, 16–18]).
Human genetic studies suggest that polymorphisms in
TLRs influence susceptibility to a variety of infections [6, 19].
We recently demonstrated that a microsatellite polymorphism
in TLR2 was significantly associated with the occurrence of
reversal reaction among leprosy patients [20]. However, this
polymorphism did not strongly influence susceptibility to
leprosy itself, nor leprosy type. Therefore, we hypothesised
that polymorphisms in TLRs other than TLR2 may influence
susceptibility to the disease. Two TLR4 polymorphisms
(896G>A [D299G] and 1196C>T [T399I]) are emerging as
major variants in TLR genes that influence human suscep-
tibility to a number of infectious diseases, including
tuberculosis [21] and invasive aspergillosis [22, 23]. In the
present study, we investigated the role of TLR4 polymor-
phisms in susceptibility to leprosy and its clinical manifes-
tations in an Ethiopian cohort.
Methods
Human subjects
The enrolment procedures and clinical definitions have been
described previously [20, 24]. Briefly, 441 leprosy patients
were drawn from the All Africa Leprosy Rehabilitation and
Training (ALERT) Multi-Drug Therapy (MDT) Field Eval-
uation Study (AMFES) [24] and 197 unrelated, healthy
controls were collected from the local population. Self-
reported ethnicity included three major ethnic groups
(Oromo, Amhara and Gurage). Leprosy types were estab-
lished on clinical grounds according to the simplified Ridley/
Jopling classification, which adds the rarely occurring
borderline borderline (BB) patients to the borderline lepro-
matous (BL) patients [25]. Twenty-five additional patients
were classified as multibacillary (MB) or paucibacillary (PB)
according to the WHO classification. Leprosy reactions were
reported only in a subgroup of 216 patients and diagnosed as
reported elsewhere [26]. Informed consent was obtained from
each study participant. The study was approved by human
subject review boards from the Armauer Hansen Research
Institute (Addis Ababa, Ethiopia), the Rockefeller University
(New York, NY), the Public Health Research Institute
(Newark, NJ), the University of Washington (Seattle, WA)
and the Western Institutional Review Board (Olympia, WA).
DNA sequencing and genotyping
Genomic DNA was extracted from whole blood using
standard protocols [20]. To determine whether there were
any polymorphisms that are unique to Ethiopians, we
sequenced the coding region of 28 individuals (9 controls
and 19 cases). The polymerase chain reaction (PCR)
products were sequenced with Big Dye Terminator v3.0
and analysed on an ABI PRISM 3730 capillary sequencer
(Applied Biosystems). Sequences were aligned and ana-
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lysed with the programs PHRED/PHRAP and CONSED
[27]. Genotyping among the whole cohort was carried out
by the MassARRAY™ technique (Sequenom, San Diego,
CA) using a chip-based matrix-assisted laser desorption/
ionisation time-of-flight mass spectrometer as previously
described [28]. Single nucleotide polymorphism (SNP)
selection included four SNPs, three previously reported
SNPs (896G>A, 1196C>T and 1530G>T [Q510H] [6, 29])
and a previously unreported SNP that was discovered by
sequencing (1976A>G [M658G]).
Statistics
Statistical analyses were performed using Stata 9 (StataCorp,
College Station, TX). All SNPs were tested for Hardy-
Weinberg equilibrium using the genhw program. Pairwise
linkage disequilibrium was assessed using the pwld
program. Haplotypes were inferred separately for each
ethnic group using the expectation-maximisation algo-
rithm implemented in the DECIPHER program (S.A.G.
E.) [30]. Haplotypes with frequencies <1.5% were
grouped together. The association of TLR4 SNPs with
susceptibility to leprosy and leprosy type was first
assessed in a multivariate logistic regression model
(general model) that did not assume any particular mode
of inheritance and accounted for the presence of each
genotype versus the wild type genotype (0/1 and 1/1, each
versus 0/0). For statistically significant associations, we
performed likelihood ratio tests for three different models
versus the general model. Each of these three models
assumed one of the following modes of inheritance:
dominant (comparing the presence of one or two copies
of the minor allele versus no copies), recessive (comparing
the presence of two copies of the minor allele versus no or one
copies) and additive (no, one or two copies of the minor allele
were coded 0, 1 and 2, respectively, assuming greater effect
with increased copy number of the minor allele). The best
fitting model was assumed in the final presentation of the
results. The association of TLR4 haplotypes with susceptibil-
ity to leprosy was calculated in a logistic regression model
including all haplotypes (each coded 0, 1 or 2 for the
presence of no, one or two copies of the haplotype), using
haplotype 1 as a reference. All analyses were adjusted for
age groups, sex and ethnicity (when applicable). Since the
sample size was limited, especially for rare SNPs, the
statistical analyses were initially performed in the whole
population. The consistency of significant results was then
verified within each ethnic group.
Bacterial strains
M. leprae strain Thai-53 was provided by Dr. James
Krahenbuhl of Lousiana State University and was propagated
and collected from the mouse footpad model as described
previously [31]. M. leprae was irradiated as described
previously [31]. Since M. leprae grows optimally at 30–
33°C, which is suboptimal for cell culture, heat-killed M.
leprae were used as described previously. Heat-killed and
viable M. leprae were compared previously and were shown
to induce similar relative cytokine response from infected
monocytes [32, 33, and G. Kaplan, unpublished data].
Human monocyte and peripheral blood mononuclear cell
stimulations
Human peripheral blood monocytes and peripheral blood
mononuclear cells (PBMCs) were isolated from healthy
donors (New Jersey Blood Center, East Orange, NJ) by
Ficoll-Paque separation and plated at a density of 3×106
PBMCs per well in a 24-well tissue culture plate. For the
preparation of monocytes, isolated PBMCs were resus-
pended in RPMI 1640 and supplemented with 1% human
AB serum (Gemini Bioproducts, Calabasas, CA), allowed
to adhere for 2 h and then washed to remove non-adherent
cells. Both adherent monocytes and PBMCs were cultured
in RPMI 1640 with 20% human serum prior to stimulation
at a multiplicity of infection (MOI) of 5:1 with heat-killed
M. leprae (ML) or stimulation with ultrapure lipopolysac-
charide (LPS; 100 ng/mL, InvivoGen, San Diego, CA).
Supernatants were collected at 48 h post-stimulation and
analysed by Luminex for the presence of multiple cytokines
(Bio-Rad, Hercules, CA).
Results
The study included 441 leprosy cases and 197 controls
(Table 1). The majority of participants were males (71.6%
of cases and 73.5% of controls). Self-reported ethnicities
were Oromo (43.8% of cases and 46.7% of controls),
Amhara (28.6% of cases and 22.3% of controls) and
Gurage (25.4% of cases and 25.9% of controls). Age
categories were not equally represented among cases and
controls (mean age 39.0 ± 15.1 years in cases versus 29.1 ±
12.4 years in controls, P<0.001). A total of 298 cases
(68.1%) were grouped into the lepromatous pole, includ-
ing 199 borderline lepromatous (BL), 81 lepromatous
lepromatous (LL) and 18 multibacillary (MB, WHO
classification). Among the 138 cases grouped into the
tuberculoid pole (31.9%), 128 were borderline tuberculoid
(BT), three polar tuberculoid (TT) and seven paucibacil-
lary (PB, WHO classification). Among the 441 patients,
216 had complete data on leprosy complications: neuritis
occurred in 133 patients (61.6%), reversal reaction in 66
(30.6%) and erythema nodosum leprosum (ENL) in 17
(7.9%).
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The TLR4 SNPs were at Hardy-Weinberg equilibrium
and their frequencies were similar among the three ethnic
groups, except for 1530G>T among Oromo (P=0.02)
(Table 2). While both 896G>A and 1196C>T are in strong
linkage disequilibrium among Caucasians (minor allele
frequency ~7%, R2>0.95), we found that this was not the
case in the present study (R2=0.32) and that 896A was ~3-
fold less frequent than 1196T, as expected in an African
population (Table 3) [34]. To investigate whether poly-
morphisms in TLR4 were associated with susceptibility to
leprosy, we compared the frequencies of TLR4 SNPs
among leprosy cases and controls, adjusting for sex, age
groups and ethnicity (Table 4). Both TLR4 SNPs 896G>A
and 1196C>T were less frequent among leprosy cases than
controls. The 896GG, GA and AA genotypes were found in
91.7, 7.8 and 0.5% of leprosy cases versus 79.9, 19.1 and
1.0% of controls, respectively (odds ratio [OR]=0.34, 95%
confidence interval [CI] 0.20–0.57, P<0.001, additive
model, Table 5). These results were still significant when
the three different ethnic groups were analysed separately
(OR=0.43, 95% CI 0.21-–.89, P=0.02 in Oromo; OR=
0.34, 95% CI 0.13-0–94, P=0.04 in Amhara and OR=0.18,
95% CI 0.05–0.65, P=0.008 in Gurage). Similarly, the
1196CC, CT and TT genotypes were found in 98.1, 1.9 and
0% of leprosy cases versus 91.8, 7.7 and 0.5% of controls,
respectively (OR=0.16, 95% CI 0.06–0.40, P<0.001,
dominant model, comparing the presence of one or two
copies of the minor allele versus no copies). Again, these
results were consistent among the three different ethnic
groups, although the significance level was not reached in
the Gurage population (P=0.02 in Oromo; P=0.04 in
Amhara and P=0.3 in Gurage, two-sided Fisher’s exact
test). A third TLR4 SNP (1530G>T) also tended to be less
frequent among leprosy cases than controls (1530GG, GT
and TT genotypes were found in 98.0, 1.8 and 0.0% of
leprosy cases versus 93.6, 5.8 and 0.6% of controls,
respectively, OR=0.38, 95% CI 0.14–1.01, P=0.05, dom-
inant model). However, the assessment of this third SNP
Table 1 Baseline characteristics of leprosy cases and control subjects
Characteristics Total leprosy cases Controls P-valuea
n (%) n (%)
Number of cases 441 (100.0) 197 (100.0)
Male gender 302 (71.6) 144 (73.5) 0.700
Ethnicityb
Oromo 193 (43.8) 92 (46.7) 0.337
Amhara 126 (28.6) 44 (22.3)
Gurage 112 (25.4) 51 (25.9)
Age groups
0–19 41 (9.9) 43 (22.2) <0.001
20–39 159 (38.5) 109 (56.2)
40–59 168 (40.7) 37 (19.1)
≥60 45 (10.9) 5 (2.6)
Leprosy typec
Lepromatous lepromatous (LL) 81 (19.7)
Borderline lepromatous (BL) 199 (48.4)
Borderline tuberculoid (BT) 128 (31.1)
Tuberculoid (TT) 3 (0.7)
Leprosy complicationsd
Neuritis 133 (61.6)
Reversal reaction 66 (30.6)
Erythema nodosum leprosum 17 (7.9)
a Double-sided Fisher’s exact test for the distribution of characteristics among all cases versus controls
b Twenty patients had other (5 cases and 9 controls) or missing (5 cases and 1 control) ethnicity
c Leprosy type was missing in five patients; 25 patients classified according the WHO as multibacillary (MB, 18 cases) or paucibacillary (PB, 7
cases) are not shown. Borderline borderline patients were classified together with BL (see Methods section). A total of 298 patients were
lepromatous (81 LL + 199 BL + 18 MB) and 138 were tuberculoid (128 BT + 3 TT + 7 PB, see Table 4)
d Complications data were available in 216 patients only
Note that the characteristics of patients and controls have already been reported [20]. They are presented here to provide the reader with an
overview of the study population.
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among the different ethnic groups was limited by the small
sample size. In the analyses by haplotypes, all haplotypes
that contained the 896A, the 1196C and/or the 1530T alleles
were associated or tended to be associated with protection
against leprosy (OR=0.48, 95% CI 0.21–1.08, P=0.08 for
haplotype 2, OR=0.12, 95% CI 0.05–0.34 for haplotype 3
and OR=0.23, 95% CI 0.08–0.69, P=0.008 for haplotype
5, compared to haplotype 1, Table 6). Together, these
results suggested that TLR4 polymorphisms are associated
with susceptibility to leprosy.
Then, we compared frequencies of the TLR4 SNPs
among leprosy patients with lepromatous (LL and BL) and
tuberculoid (BT and TT) leprosy, adjusting for sex, age
groups and ethnicity (Table 4). There was an association at
the limit of the significant level between the 1196C>T SNP
and lepromatous leprosy. The 1196CC, CT and TT
genotypes were found in 98.9, 1.1 and 0% of lepromatous
leprosy patients versus 96.2, 3.8 and 0% of tuberculoid
patients, respectively (OR=0.23, 95% CI 0.05–0.99, P=
0.05, dominant model). No significant association was
found when lepromatous lepromatous patients were com-
pared with the other leprosy patients. Together, these results
suggested that TLR4 SNPs are not strongly associated (if at
all) with the type of leprosy.
Next, we investigated whether TLR4 polymorphisms
were associated with the occurrence of leprosy complica-
tions. No association was found between TLR4 SNPs and
neuritis. The 1530T allele was more frequent in patients
with reversal reaction (2/15 [13%] in patients with reversal
reaction versus 3/177 [1.7%] in those without reversal
reaction, P=0.05, Fisher’s exact test) and ENL (4/58 [6.9%]
in patients with ENL versus 1/133 [0.7%] in those without
ENL, P=0.03). However, the interpretation of these results
is limited by the small sample size, which prevented
stratification into separate ethnic groups and the use of
multivariable models.
Table 2 Allelic and haplotypic frequencies of Toll-like receptor 4 (TLR4) single nucleotide polymorphisms (SNPs) in the three Ethiopian
populations
SNP Amino acid change rs number Oromo Amhara Gurage P-valueb
n=285 n=170 n=163
MAF HWEa MAF HWEa MAF HWEa
896G>A D299G 4986790 0.069 0.12 0.064 0.50 0.052 1.00 0.604
1196C>T T399I 4986791 0.022 1.00 0.021 0.06 0.016 1.00
1530G>T Q510H 5030719 0.030 0.02 0.010 1.00 0.007 1.00
1976A>G M658G N/Ac 0.024 1.00 0.019 1.00 0.010 1.00
Haplotyped
1) ACGA - - 0.907 - 0.923 - 0.941 - 0.235
2) GCGA - - 0.024 - 0.030 - 0.028 -
3) GTGA - - 0.020 - 0.021 - 0.016 -
4) ACGG - - 0.020 - 0.015 - 0.006 -
5) GCTA - - 0.024 - 0.009 - 0.003 -
MAF = minor allele frequency; HWE = Hardy-Weinberg equilibrium test
a Hardy-Weinberg equilibrium was calculated for each locus and the P-value is reported. A P-value of <0.05 indicates that the alleles are not in
HWE
bDouble-sided Fisher’s exact test for the overall distribution of alleles/haplotypes among the three ethnic groups
c SNP 1976A>G has not been previously reported
d Haplotypes with an MAF <1.5% in the whole population are not shown
TLR4 SNPs were not in linkage disequilibrium with any of the TLR2 polymorphisms that have been previously analysed in this population [20]
Table 3 Linkage disequilibrium between the TLR4 SNPs in all ethnic
groups
SNPs 896G>A 1196C>T 1530G>T 1976A>G
896G>A 0.06
1196C>T 0.32 0.02
1530G>T 0.26 0.00 0.02
1976A>G 0.00 0.00 0.00 0.02
Pairwise linkage disequilibrium (LD) were calculated with the
pwld program developed in Stata 9 (StataCorp, College Station,
TX). Off-diagonal elements are estimates of R2 , assuming Hardy-
Weinberg equilibrium. The diagonal elements are minor allele
frequencies (in italics). LD between 896G>A and 1196C>T was
similar among the three ethnic groups (R2 = 0.34 in Oromo, R2 =
0.32 in Amhara and R2 = 0.27 in Gurage)
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Finally, we examined the cellular mechanism of how M.
leprae modulates TLR4-mediated immune responses. We
previously demonstrated that irradiated M. leprae or its cell
wall extracts stimulate TNF-α secretion through TLR2, but
not TLR4, in bone marrow-derived macrophages [35]. In
HEK293 cells transfected with an NF-κB luciferase
construct, we also found that TLR2, but not TLR4, mediates
signalling in response to stimulation with irradiated M.
leprae or its cell wall extracts (data not shown and [35]).
Together, these results suggested that M. leprae does not
directly stimulate an immune response through TLR4,
which is consistent with the absence of LPS in its cell wall.
We hypothesised that M. leprae modulates TLR4-
mediated immune responses by regulating shared compo-
nents of the downstream TLR signalling pathway. To test
this hypothesis, we isolated and stimulated human mono-
cytes with LPS and M. leprae and measured cytokine
production in culture supernatants. In contrast to LPS, M.
leprae did not induce IL-1β, IL-6 or IL-12p70 in mono-
cytes (Fig. 1A, B, C). To examine whether M. leprae
inhibits or merely fails to activate cytokine production, we
examined cytokine production with mixed stimulations. In
monocytes that were concurrently co-stimulated with M.
leprae and LPS, cytokine production was similar to that of
LPS alone. In contrast, when cells were pre-stimulated with
M. leprae for 5 or 24 h and then stimulated with LPS, IL-
1β production was lower in comparison to stimulation with
LPS alone (Fig. 1A). A similar trend was observed for IL-6
production after 24 h of M. leprae pre-stimulation, but the
differences were not statistically significant (Fig. 1B). In
contrast to IL-6 and IL-1β, there was no difference in IL-
12p70 production among the different conditions tested
(Fig. 1C). As a control, we repeated the experiment in the
opposite stimulation order (LPS followed by M. leprae) and
found no difference in cytokine levels. Next, we examined
whether M. leprae modulated LPS-induced signalling in
PBMCs. Similar to monocytes, we found that the pre-
stimulation of PBMCs with M. leprae for 24 h led to
decreased LPS-induced secretion of IL-6 in comparison to
stimulation with LPS alone (Fig. 1E). IL-1β levels were
also lower in the PBMCs that were pre-treated with M.
leprae for 24 h, although the difference was not statistically
significant (Fig. 1D). Similar to monocytes, no differences
in IL-6 or IL-1β levels were observed when the cells were
stimulated with M. leprae after LPS. There was no
difference among the different stimulation conditions when
comparing levels of IL-12p70 or several T cell cytokines
(IFN-γ, IL-4 or IL-17). Together, these results suggest that
M. leprae inhibits the LPS induction of IL-1β and IL-6
secretion from monocytes. Furthermore, this effect was
selective and not found for T-cell cytokines or other
monocyte cytokines, such as IL-12p70.
Table 4 Association of TLR4 SNPs with leprosy and leprosy type
SNP Leprosy
n=441
Controls
n=197
P-value Lepromatous,
n=298
Tuberculoid,
n=138
P-value Lepromatous
Lepromatous,
n=81
Other,
n=355
P-value
n (%) n (%) n (%) n (%) n (%) n (%)
896G>A
G/G 375 (91.7) 155 (79.9) ref. 256 (91.8) 119 (91.5) ref. 73 (91.3) 302 (91.8) ref.
G/A 32 (7.8) 37 (19.1) <0.001 22 (7.9) 10 (7.7) 0.95 7 (8.8) 25 (7.6) 0.86
A/A 2 (0.5) 2 (1.0) 0.08 1 (0.4) 1 (0.8) - 0 (0.0) 2 (0.6) -
1196T>C
T/T 407 (98.1) 179 (91.8) ref. 282 (98.9) 125 (96.2) ref. 78 (98.7) 329 (97.9) ref.
T/C 8 (1.9) 15 (7.7) <0.001 3 (1.1) 5 (3.8) 0.05 1 (1.3) 7 (2.1) 0.58
C/C 0 (0.0) 1 (0.5) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
1530G>T
G/G 391 (98.0) 162 (93.6) ref. 271 (98.2) 120 (97.6) ref. 75 (98.7) 316 (97.8) ref.
G/T 7 (1.8) 10 (5.8) 0.06 5 (1.8) 2 (1.6) 0.72 1 (1.3) 6 (1.9) 0.98
T/T 1 (0.3) 1 (0.6) 0.56 0 (0.0) 1 (0.8) - 0 (0.0) 1 (0.3) -
1976A>G
A/A 386 (96.5) 164 (94.8) ref. 267 (95.7) 119 (98.3) ref. 73 (94.8) 313 (96.9) ref.
A/G 14 (3.5) 9 (5.2) 0.64 12 (4.3) 2 (1.7) 0.29 4 (5.2) 10 (3.1) 0.62
P-values are calculated in a logistic regression model that did not assume any particular mode of inheritance and accounted for the presence of each
genotype (0/1 and 1/1) versus the wild type genotype (0/0), adjusted for age group, sex and ethnicity (general model). For statistically significant
associations, we performed a likelihood ratio tests for three different models (dominant, recessive and additive) versus the general model. The best fitting
models are shown in Table 5. The numbers of individuals with assessable genotypes may differ slightly for the different SNPs
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Discussion
In this paper, we showed that two SNPs in TLR4 (896G>A
[D299G] and 1196C>T [T399I]) were associated with
protection against leprosy in an Ethiopian cohort of leprosy
patients and healthy controls. We also demonstrated that M.
leprae downregulates TLR4-mediated cytokine production
in monocytes.
Recent studies have also found associations of TLR SNPs
and leprosy susceptibility. An SNP in TLR1 (T1805G
[I602S]) was associated with M. leprae infection [36–38].
Another study reported that a TLR2 SNP (C2029T [R677W])
located in a critical region of the Toll-interleukin receptor
(TIR) domain was associated with lepromatous leprosy in
Table 6 Association of TLR4 haplotypes with leprosy
Haplotype Leprosy (n = 441) vs. controls (n = 197)
OR (95% CI) P-value)
1) ACGA ref. -
2) GCGA 0.48 (0.21–1.08) 0.08
3) GTGA 0.12 (0.05–0.34) <0.001
4) ACGG 0.62 (0.23–1.67) 0.3
5) GCTA 0.23 (0.08–0.69) 0.008
P-values are calculated in a logistic regression model including all
haplotypes (each coded 0, 1 or 2, for the presence of no, one or two
copies of the haplotype), using haplotype 1 as a reference. The results
are adjusted for age group, sex and ethnicity
Fig. 1 Monocyte and peripheral blood mononuclear cell (PBMC)
cytokine response to mixed stimulation with Mycobacterium leprae
and lipopolysaccharide (LPS). Human peripheral blood monocytes
and PBMCs were isolated and infected at a multiplicity of infection
(MOI) of 5:1 with heat-killed M. leprae (ML), LPS (100 ng/mL), M.
leprae and LPS simultaneously, or pre-stimulation with either M.
leprae or LPS for 5 or 24 h, followed by treatment with the other
stimulus. Supernatants were collected at 48 h post-stimulation and
analysed by Luminex for the presence of multiple cytokines. The
results are the means ± standard error of three experiments (donors)
performed in duplicate, with the exceptions of IL-1β production from
monocytes (five donors) and IL-6 production from monocytes (four
donors). A two-tailed paired t-test was used for statistical analysis (*P<
0.05, **P<0.005, #P<0.001, in comparison to LPS alone)
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Korea [39]. While an amino-acid substitution at this location
completely abolished TLR2 signalling in transfected cells
[35], subsequent studies revealed that this supposedly
functional SNP was, in fact, located in a highly homologous
pseudogene region located 23 kB upstream of the TLR2 gene
[40]. More recently, we showed that a microsatellite poly-
morphism located in TLR2 significantly increased the risk of
leprosy reversal reaction [20]. Allelic length variations in the
microsatellite may influence promoter activity and modify
TLR2 function through alteration of its expression level [41].
However, the TLR2 microsatellite polymorphism associated
with leprosy reversal reaction did not strongly influence
susceptibility to leprosy itself.
In the present study, we examined whether polymorphisms
in TLR4 influenced susceptibility to or the clinical character-
istics of leprosy in an Ethiopian cohort. We found that the
minor alleles of two TLR4 SNPs (896G>A [D299G] and
1196C>T [T399I]) were associated with a reduced risk of
developing leprosy. Such a protective effect is in contrast
with most studies. In fact, TLR4 896A and 1196T were
frequently associated with increased susceptibility to patho-
gens, including Gram-negative bacteria, Brucella species,
respiratory syncytial virus (RSV), Plasmodium falciparum
and Candida albicans (reviewed in [6]).
Our data support the hypothesis that, in the case of
specific infections, dysfunctional TLR SNPs may reduce,
instead of increase, susceptibility to infections. This
hypothesis is also supported by previous observations: the
dysfunctional allele of TLR1 1805G (602S) exerted a
protective effect against leprosy [37]; the dysfunctional
2258G/A (R753Q) was shown to increase the risk of
tuberculosis [42] but to protect against Lyme borreliosis
[43]; finally, as it is the case for leprosy, TLR4 896A and
1196T were shown to protect from Legionnaire’s disease
[44]. The reason why a specific TLR allele exerts a protective
effect against some infections and an increased risk for others
is unknown. These differences reflect the complexity of
human immune responses to infectious agents and may result
from co-evolving selective pressures in hosts and pathogens.
TLR4 896G>A and 1196C>T have been intensively exam-
ined in functional and genetic epidemiological studies. 896A
was associated with LPS hypo-responsiveness after the in
vivo inhalation of endotoxin [23, 45]. In vitro cellular
investigations also suggested that 299G and/or 399I was
unable to mediate LPS signalling in some [23, 46] but not all
cell types [47–49]. These seemingly contradictory findings
may be explained by the use of small sample sizes, which
resulted in differences with borderline statistical significance;
comparison of different cell types; use of different doses and
types of LPS; and measurement of different cytokines and
inflammatory markers. Taken together, these studies suggest
that SNPs 896G>A and 1196C>T partially influence
inflammatory pathways under some experimental conditions.
While TLR2 has been clearly implicated in the innate
immune response toM. leprae, the role of TLR4 is currently
unknown. We previously found that irradiated M. leprae or
its cell wall extracts stimulated TNF-α production through
TLR2, but not TLR4 [35]. If live M. tuberculosis signals
through TLR4, then it is plausible that M. leprae may do so
similarly [13]. Alternatively, TLR4 may modulate inflam-
matory processes that influence leprosy disease manifes-
tations but are not attributable to direct stimulation by M.
leprae. Consistent with this hypothesis, we found that the
stimulation of monocytes with M. leprae inhibited their
subsequent response to TLR4 stimulation with LPS. There
are several possible mechanisms of this inhibitory effect,
including tolerance, a well-described phenomenon where
prior exposure of cells to TLR ligands results in a transient
hypo-responsive state that is refractory to additional
stimulation [50]. Several mechanisms have been proposed
for tolerance, including the alteration of expression levels
of negative and positive regulators of the TLR signalling
pathway. For example, IRAK-M is a negative regulator of
the TLR signalling pathway that is downstream of both
TLR2 and TLR4 and is involved in endotoxin tolerance
[51]. M. leprae may alter the expression of molecules such
as IRAK-M through TLR2 stimulation and, ultimately,
modulate LPS/TLR4 responsiveness through such a shared
signalling intermediate. An alternative mechanism could be
from direct inhibitory effects of an M. leprae molecule on
the TLR signalling pathway. There are several precedents
for this mechanism, including YopJ inhibition of MAPK
signalling by Yersinia pestis [52] and the recently described
TIR domain containing proteins (Tcps) in Escherichia coli
that bind MyD88 and inhibit TLR-induced signalling
pathways [53]. Future studies will address these possible
mechanisms of M. leprae inhibition of TLR4 signalling.
The alteration of monocyte responses to M. leprae by TLR4
polymorphisms via these different mechanisms could
modulate the growth of bacilli, the nature and degree of
the innate immune response, and the subsequent adaptive
immune response. TLRs are known to influence Th1–Th2
pathway development in mice and such immunomodulatory
effects could operate in humans as well [7]. TLR4 poly-
morphisms may modulate several of these immunologic
effects and, thereby, influence overall susceptibility to
leprosy. Future studies will address which cellular immune
responses are modulated by TLR4 polymorphisms
This study was limited by the low frequency of the
minor alleles of TLR4. This issue was of particular concern
for the analyses of leprosy types (lepromatous versus
tuberculoid), as well as for leprosy complications, for
which it prevented stratification into separate ethnic groups
and the use of multivariable models. However, the analyses
of susceptibility to leprosy itself were performed in larger
sample sizes. In this case, initial analyses were performed
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for the whole population, including the three major ethnic
groups. In order to limit the risk of population stratification,
we also performed the analyses in the three different groups
separately. Overall, most observations were consistent
among the three different ethnic groups.
In summary, our data show that polymorphisms in TLR4
are associated with susceptibility to leprosy in Ethiopian
patients. It suggests that polymorphisms in individual TLRs
may influence different clinical manifestations of the disease.
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